AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands

by Barry101 | Feb 10, 2021 | Press Release, Uncategorized

Early Access Program Will Also Allow Further Treatment of Patients Treated Under the Previous Ampligen Early Access ProgramOCALA, Fla., Feb. 10, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Dutch Health and Youth Care Inspectorate...

AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials

by Barry101 | Feb 5, 2021 | Press Release, Uncategorized

OCALA, Fla., Feb. 05, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATM’s Equity Distribution Agreement (EDA). Management believes, based on the company’s current...

AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

by Barry101 | Jan 29, 2021 | Press Release, Uncategorized

AIM is Working to Develop an Effective COVID-19 Intranasal TherapyOCALA, Fla., Jan. 29, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the...

AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

by Barry101 | Jan 15, 2021 | Press Release, Uncategorized

AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestonesOCALA, Fla., Jan. 15, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its...

AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date

by Barry101 | Jan 11, 2021 | Press Release, Uncategorized

OCALA, Fla., Jan. 11, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week’s planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels’...

AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen

by Barry101 | Jan 6, 2021 | Press Release, Uncategorized

AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestonesOCALA, Fla., Jan. 06, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today...